Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura™
August 16 2016 - 8:47AM
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that
the Data and Safety Monitoring Board (DSMB) completed its first
pre-planned safety review of the Phase 3 SOLUTION clinical study of
Sollpura™ in cystic fibrosis patients with exocrine pancreatic
insufficiency. The DSMB had “no concerns regarding safety of the
data to date, and voted that the study continue without
modification to the protocol or charter.”
This follows six positive reviews by a separate independent
blisibimod DSMB for the CHABLIS-SC1 clinical study in patients with
lupus and the BRIGHT-SC clinical study in patients with IgA
nephropathy that recommended that the studies continue without
modification, with the latest positive review occurring in June of
this year.
About Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals is a biopharmaceutical company focused
on developing and commercializing products to treat serious and
life-threatening diseases, including lupus, lupus with
glomerulonephritis, IgA nephropathy, and exocrine pancreatic
insufficiency due to cystic fibrosis. Additional information on the
Company can be found at www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on Anthera's expectations as
of the date of this press release and are subject to certain risks
and uncertainties that could cause actual results to differ
materially as set forth in Anthera's public filings with the SEC,
including Anthera's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2016. Anthera disclaims any intent or obligation to
update any forward-looking statements, whether because of new
information, future events or otherwise, except as required by
applicable law.
CONTACT: Nikhil Agarwal of Anthera Pharmaceuticals, Inc.
nagarwal@anthera.com or 510.856.5600 x5621
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Sep 2023 to Sep 2024